{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:31:00Z","timestamp":1792009860135,"version":"4.4.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Our previous studies have demonstrated that tumor-infiltrating lymphocytes (TILs), including normal B cells, T cells, and natural killer (NK) cells, in diffuse large B-cell lymphoma (DLBCL) have a significantly favorable impact on the clinical outcomes of patients treated with standard chemoimmunotherapy. In this study, to gain a full overview of the tumor immune microenvironment (TIME), we assembled a flow cytometry cohort of 102 patients diagnosed with DLBCL at the Duke University Medical Center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected diagnostic flow cytometry data, including the proportion of T cells, abnormal B cells, normal B cells, plasma cells, NK cells, monocytes, and granulocytes in fresh biopsy tissues at clinical presentation, and analyzed the correlations with patient survival and between different cell populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that low T cell percentages in all viable cells and low ratios of T cells to abnormal B cells correlated with significantly poorer survival, whereas higher percentages of normal B cells among total B cells (or high ratios of normal B cells to abnormal B cells) and high percentages of NK cells among all viable cells correlated with significantly better survival in patients with DLBCL. After excluding a small number of patients with low T cell percentages, the normal B cell percentage among all B cells, but not T cell percentage among all cells, continued to show a remarkable prognostic effect. Data showed significant positive correlations between T cells and normal B cells, and between granulocytes and monocytes. Furthermore, we constructed a prognostic model based on clinical and flow cytometry factors, which divided the DLBCL cohort into two equal groups with remarkable differences in patient survival and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>TILs, including normal B cells, T cells, and NK cells, are associated with favorable clinical outcomes in DLBCL, and flow cytometry capable of quantifying the TIME may have additional clinical utility  for prognostication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2024.1335689","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T23:28:27Z","timestamp":1706484507000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Tiantian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun Y.","family":"Xu-Monette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Lagoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadee","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Pina-Oviedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"New Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"102443","DOI":"10.1016\/j.ctrv.2022.102443","article-title":"Treatment strategies for patients with diffuse large B-cell lymphoma","volume":"110","author":"Poletto","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100750","DOI":"10.1016\/j.esmoop.2022.100750","article-title":"How I treat diffuse large B-cell lymphoma","volume":"8","author":"Melchardt","year":"2023","journal-title":"ESMO Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1139482","article-title":"Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879015","article-title":"PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype","volume":"133","author":"Godfrey","year":"2019","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.134612","article-title":"Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166070","article-title":"Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma","volume":"133","author":"Apollonio","year":"2023","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3390\/jcm9082418","article-title":"Inflammatory cells in diffuse large B cell lymphoma","volume":"9","author":"Tamma","year":"2020","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.24710901","article-title":"Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL","volume":"29","author":"Xu-Monette","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2230137","article-title":"Immune-based therapies in diffuse large B-cell lymphoma","volume":"32","author":"McCurry","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.8.2863","article-title":"Recent advances in flow cytometry: application to the diagnosis of hematologic Malignancy","volume":"90","author":"Jennings","year":"1997","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6926(03)00068-9","article-title":"Flow cytometry in lymphoma diagnosis and prognosis: useful","volume":"16","author":"Stetler-Stevenson","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.011","article-title":"Flow cytometry: Surface markers and beyond","volume":"143","author":"Delmonte","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.1206351","article-title":"Immunology","volume":"332","author":"Benoist","year":"2011","journal-title":"Flow cytometry amped up. Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21322","article-title":"Improved detection of diffuse large B-cell lymphoma by flow cytometric immunophenotyping-Effect of tissue disaggregation method","volume":"90","author":"Vallangeon","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPWEX5YY4PHSCN","article-title":"Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: a comparative study of 67 cases","volume":"143","author":"Shi","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2023.04.004","article-title":"How to design and validate a clinical flow cytometry assay","volume":"43","author":"Lagoo","year":"2023","journal-title":"Clin Lab Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/cas.12307","article-title":"De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity","volume":"105","author":"Tokunaga","year":"2014","journal-title":"Cancer Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02649.x","article-title":"Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study","volume":"112","author":"Xu","year":"2001","journal-title":"Br J haematology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23398","article-title":"CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy","volume":"88","author":"Keane","year":"2013","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3534-z","article-title":"Novel risk stratification of de novo diffuse large B cell lymphoma based on tumour-infiltrating T lymphocytes evaluated by flow cytometry","volume":"98","author":"Chen","year":"2019","journal-title":"Ann Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.687911","article-title":"Flow cytometry-assessed PD1\/PDL1 status in tumor-infiltrating lymphocytes: A link with the prognosis of diffuse large B-cell lymphoma","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-1-4939-9650-6_5","article-title":"Guidelines for gating flow cytometry data for immunological assays","volume":"2032","author":"Staats","year":"2019","journal-title":"Methods Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.modpat.2023.100224","article-title":"Prognostic impact of the immunoscore based on whole-slide image analysis of CD3+ Tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma","volume":"36","author":"Han","year":"2023","journal-title":"Modern Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1998.tb01385.x","article-title":"A comparison of flow cytometry and immunohistochemistry in human colorectal cancers","volume":"106","author":"Diederichsen","year":"1998","journal-title":"APMIS Acta pathologica microbiologica immunologica Scandinavica"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.14158","article-title":"Factors determining whether diffuse large B-cell lymphoma samples are detected by flow cytometry","volume":"45","author":"Peng","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13046-016-0404-1","article-title":"Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls","volume":"35","author":"Cordone","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2825(1999)13:5<224::AID-JCLA6>3.0.CO;2-5","article-title":"Immunophenotyping by flow cytometry of fine needle aspirates in the diagnosis of lymphoproliferative disorders: A retrospective study","volume":"13","author":"Henrique","year":"1999","journal-title":"J Clin Lab Anal"},{"key":"B41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1309\/BA3U-RMTU-D7UJ-M8DR","article-title":"Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation","volume":"116","author":"Bertram","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020597","article-title":"Macrophage heterogeneity in the single-cell era: facts and artifacts","volume":"142","author":"Hume","year":"2023","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-862292","article-title":"Single-cell RNA-Seq of follicular lymphoma reveals Malignant B-cell types and coexpression of T-cell immune checkpoints","volume":"133","author":"Andor","year":"2019","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discovery"},{"key":"B45","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","article-title":"Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels","volume":"22","author":"Roider","year":"2020","journal-title":"Nat Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.molcel.2019.05.003","article-title":"Single-cell RNA sequencing in cancer: lessons learned and emerging challenges","volume":"75","author":"Suv\u00e0","year":"2019","journal-title":"Mol Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20188746","article-title":"Current best practices in single-cell RNA-seq analysis: a tutorial","volume":"15","author":"Luecken","year":"2019","journal-title":"Mol Syst Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201900228","article-title":"Single-cell RNA sequencing in hematological diseases","volume":"20","author":"Zhu","year":"2020","journal-title":"Proteomics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e32834a69ae","article-title":"Polychromatic flow cytometry in the clinical laboratory","volume":"43","author":"Sewell","year":"2011","journal-title":"Pathology"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59266","article-title":"Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice","volume":"121","author":"Horikawa","year":"2011","journal-title":"J Clin Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cll.2017.07.001","article-title":"Flow cytometry of B-cell neoplasms","volume":"37","author":"Kroft","year":"2017","journal-title":"Clin Lab Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP3C2QZZBPTMLB","article-title":"Flow cytometric analysis of surface light chain expression patterns in B-cell lymphomas using monoclonal and polyclonal antibodies","volume":"136","author":"Horna","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/94.3.280","article-title":"Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section method","volume":"94","author":"Witzig","year":"1990","journal-title":"Am J Clin Pathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21756","article-title":"The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms","volume":"96","author":"Seegmiller","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"New Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"New Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.018","article-title":"Cord blood CAR-NK cells: favorable initial efficacy and toxicity but durability of clinical responses not yet clear","volume":"37","author":"Karadimitris","year":"2020","journal-title":"Cancer Cell"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.200105","article-title":"T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma","volume":"104","author":"Leivonen","year":"2019","journal-title":"Haematologica"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30021-X","article-title":"Improving R-CHOP in diffuse large B-cell lymphoma is still a challenge","volume":"20","author":"Jardin","year":"2019","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.66","article-title":"Modulatory effects of bortezomib on host immune cell functions","volume":"7","author":"Pellom","year":"2015","journal-title":"Immunotherapy"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900321","article-title":"Dissection of the effects of JAK and BTK inhibitors on the functionality of healthy and Malignant lymphocytes","volume":"203","author":"Hofland","year":"2019","journal-title":"J Immunol (Baltimore Md. 1950)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1101\/2020.06.10.135632","article-title":"Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by ibrutinib via inhibition of JAK2","volume":"12","author":"Barbarino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PloS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1335689\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T23:28:31Z","timestamp":1706484511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1335689\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2024.1335689"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1335689","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"article-number":"1335689"}}